Peginterferon Alfa-2a And Ribavirin
Recommended · restricted HepatologyRestrictedSecond-line line
Treatment of chronic hepatitis C in patients 18 years or older who have compensated liver disease and have failed one prior attempt at interferon-based therapies (non-pegylated or pegylated).
1
Submissions
1 resub
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Jul 2010Recommended · restricted
vs peginterferon alfa-2b plus ribavirin (Pegatron CT)
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated
The PBAC noted that at the prices proposed in the submission, Pegasys RBV will be cost-saving compared to Pegatron CT. PBAC · 2010
Decision context
PopulationAdults aged 18 years or older with compensated liver disease and chronic hepatitis C who have failed one prior course of interferon-based therapy (pegylated or non-pegylated), with or without ribavirin, classified into subgroups by prior treatment type and viral response status (non-responders or relapsers) and HCV genotype.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2010 | Recommended · restricted | peginterferon alfa-2b plus ribavirin (Pegatron CT) | — | RCT · SVR |